45 completed, 32 recruiting, 19 unknown, 17 terminated. 59 Phase 2, 56 Phase 1, 23 Not applicable, 6 Phase 4, 4 Phase 3.
Follow Meningeal Carcinomatosis: new trials by email Literature Review of Meningeal Carcinomatosis trials Research Report on Meningeal Carcinomatosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Wearable-Triggered Digital Safety Net for Real-Time Monitoring & Intervention in Leptomeningeal Metastasis Calibration Phase, Stepped Wedge Intervention Phase - Leptomeningeal Metastasis | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 48 | 2026-11-01 | 2026-09-03 |
| BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI) - Leptomeningeal Metastasis, Breast Cancer | Not applicable | Recruiting | University of Miami | 40 | 2026-10-13 | 2026-10-23 |
| Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases Intrathecal and systemic administration of Trastuzumab Rezetecan - Leptomeningeal Metastases, Solid Tumors | Phase 2 | Not yet recruiting | Jiuda Zhao | 28 | 2026-09-01 | 2026-09-22 |
| Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI. Thiotepa - Leptomeningeal Metastasis | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 50 | 2026-09-01 | 2026-08-21 |
| Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases 186RNL - Leptomeningeal Metastases | Phase 1 | Not yet recruiting | NYU Langone Health | 29 | 2026-07-01 | 2026-06-29 |
| Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer Sacituzumab tirumotecan - EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis | Phase 1 | Not yet recruiting | Henan Cancer Hospital | 15 | 2026-06-23 | 2026-07-14 |
| Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab - Brain Metastases, Leptomeningeal Metastasis | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-06-15 | 2026-06-17 | |
| QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors QH101 Cell Injection - Brain Metastasis, Meningeal Metastasis | Early Phase 1 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 7 | 2026-05-31 | 2026-06-18 |
| Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Zorifertinib Plus Intra-Ommaya CSF Chemotherapy - NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 38 | 2026-05-30 | 2026-04-24 |
| Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis Furmonertinib 320mg qod po, Furmonertinib 160mg qd po - NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis | Not applicable | Recruiting | Guangzhou University of Traditional Chinese Medicine | 42 | 2026-03-01 | 2026-04-02 |
| Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients - Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer | Not applicable | Recruiting | Second Affiliated Hospital of Nanchang University | 30 | 2026-02-15 | 2026-04-23 |
| Zorifertinib With Osimertinib for NSCLC With Meningeal Progression Zorifertinib and Osimertinib Combination Therapy - Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment | Phase 1 | Recruiting | Alpha Biopharma (Jiangsu) Co., Ltd. | 42 | 2026-01-31 | 2026-06-22 |
| Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer Sacituzumab Govitecan, Pemetrexed - Leptomeningeal Metastases | Phase 1 / Phase 2 | Recruiting | Guangzhou Medical University | 34 | 2026-01-01 | 2025-09-29 |
| Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-12-22 | 2025-12-26 |
| A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases SHR-A1811, radiotherapy - Breast Cancer, Brain Metastases | Phase 1 / Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 51 | 2025-09-30 | 2025-09-17 |
| Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. Pemetrexed - Leptomeningeal Metastasis | Phase 2 | Recruiting | Guangzhou Medical University | 36 | 2025-09-01 | 2026-01-30 |
| Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases 186RNL - Leptomeningeal Metastasis | Phase 1 / Phase 2 | Recruiting | Cerenome | 24 | 2025-07-02 | 2026-09-09 |
| AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study Lung Cancer (NSCLC), Leptomeningeal Metastasis | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 142 | 2025-07-01 | 2025-06-05 | |
| Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 BioTTT001 injection - Meningeal Metastasis | Phase 1 / Phase 2 | Recruiting | Henan Cancer Hospital | 42 | 2025-06-25 | 2025-12-04 |
| High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Combination therapy prospective cohort - Non Small Cell Lung Cancer, EGFR Mutation | Phase 2 | Not yet recruiting | Qiming Wang | 100 | 2025-05-15 | 2025-05-14 |
Showing 20 of 146. Sign in to see all of them.
Brain Neoplasms (34) · Carcinoma, Non-Small-Cell Lung (30) · Breast Neoplasms (24) · Central Nervous System Neoplasms (15) · Lung Neoplasms (12) · Meningeal Neoplasms (11) · Leukemia (8) · Lymphoma (8) · Neoplasm Metastasis (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Recurrence (7) · Burkitt Lymphoma (6) · Medulloblastoma (6) · Dendritic Cell Sarcoma, Interdigitating (5)
Neoplasms by Site (145) · Nervous System Diseases (145) · Nervous System Neoplasms (145) · Neoplasms (142) · Meningeal Neoplasms (135) · Central Nervous System Neoplasms (131) · Brain Diseases (35) · Central Nervous System Diseases (35) · Lung Diseases (34) · Respiratory Tract Diseases (34) · Respiratory Tract Neoplasms (34) · Thoracic Neoplasms (34) · Bronchial Neoplasms (30) · Carcinoma, Bronchogenic (30) · Skin Diseases (25)
Pemetrexed (20) · Bevacizumab (10) · Radiotherapy (8) · Spinal Puncture (7) · Magnetic Resonance Spectroscopy (6) · Methotrexate (6) · osimertinib (6) · Specimen Handling (5) · Topotecan (5) · aflutinib (5) · Radiotherapy, Intensity-Modulated (4) · Temozolomide (4) · Trastuzumab (4) · Dexamethasone (3) · AZD3759 (2)
Guangzhou Medical University (8) · Duke University (5) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · The First Hospital of Jilin University (5) · Centre Oscar Lambret (4) · City of Hope Medical Center (4) · Henan Cancer Hospital (4) · Hui Bu (4) · NYU Langone Health (4) · National Cancer Institute (NCI) (4) · Second Affiliated Hospital of Nanchang University (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Chinese Academy of Medical Sciences (3) · H. Lee Moffitt Cancer Center and Research Institute (3)
United States (61) · China (54) · France (8) · Netherlands (3) · Taiwan (3) · Canada (2) · Denmark (2) · South Korea (2) · Spain (2) · Switzerland (2) · Australia (1) · Austria (1) · Germany (1) · Italy (1) · Japan (1)
Zhenyu Pan (3) · Zhenyu Pan, Professor (3) · D. Brandsma, MD, PhD (2) · Darell D. Bigner, MD, PhD (2) · Henry S. Friedman, MD (2) · Hui Bu (2) · Jianping Xiao (2) · Jonathan Yang, MD, PhD (2) · Liu Anwen, Phd (2) · Morris D. Groves, MD (2) · Susan Blaney, MD (2) · Susan M. Blaney, MD (2) · Zhenyu Pan, PhD,MD (2) · Andrew Brenner, PhD (1) · Andrew Dhawan, MD, DPhil (1)
PMID 27243238, PMID 31809241, PMID 15117425, PMID 26334749, PMID 26827696, PMID 29151359, PMID 30059262, PMID 9533527, PMID 10501910, PMID 11937001, PMID 14059058, PMID 1447744, PMID 15118073, PMID 15118125, PMID 15844174, PMID 15886314, PMID 15897941, PMID 16391300, PMID 16533779, PMID 16642476, PMID 16855840, PMID 16983123, PMID 17308042, PMID 17312328, PMID 17315026, PMID 17374728, PMID 17894407, PMID 17909804, PMID 18172267, PMID 18447671, PMID 19470276, PMID 19738466, PMID 20087963, PMID 20573926, PMID 20627894, PMID 20689429, PMID 21599552, PMID 21874597, PMID 21910214, PMID 22487432, PMID 23354655, PMID 23717798, PMID 24002608, PMID 24705333, PMID 24893802, PMID 24893891, PMID 24991768, PMID 25142885, PMID 25175099, PMID 25336382
P30CA033572 (2), 2008 (1), 2009 (1), 2019 (1), P30CA015704 (1), P30CA043703 (1), P30CA060553 (1), R03CA208547 (1), U01CA081457 (1), U10CA098543 (1), U10CA180868 (1), UM1CA186712 (1)